No speedy nasal roll­out for Ox­ford/As­traZeneca’s Covid-19 jab af­ter PhI flop

Ox­ford/As­traZeneca’s nasal spray vac­cine per­formed poor­ly in an ear­ly-stage study, squash­ing hopes for a quick ad­vance­ment of the duo’s orig­i­nal for­mu­la­tion via an in­oc­u­la­tion at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.